Commentary: Allergies, EDN, and the Psychosocial Burden of EoE, February 2024February 1, 2024Upper GI Tract
Commentary: Combination therapies and immunotherapy in HCC, December 2022November 29, 2022Hepatocellular Carcinoma
Microwave ablation: An alternative to resection in HCC with BCLC stage 0November 18, 2022Hepatocellular Carcinoma
Sequence of radiotherapy and TACE affects the prognosis of HCC with portal vein tumor thrombusNovember 18, 2022Hepatocellular Carcinoma
Atezolizumab+bevacizumab: A better first-line treatment option for unresectable HCC than lenvatinibNovember 18, 2022Hepatocellular Carcinoma
Alpha-fetoprotein and carbohydrate antigen 19-9: Prognostic markers in HCC after hepatectomyNovember 18, 2022Hepatocellular Carcinoma
HAIC+lenvatinib+sequential ablation: An effective and safe treatment option for advanced HCCNovember 18, 2022Hepatocellular Carcinoma
HCC: Atezolizumab+bevacizumab treatment outcome unaffected by the underlying liver etiologyNovember 18, 2022Hepatocellular Carcinoma
Immune checkpoint inhibitor rechallenge is effective and safe in HCCNovember 18, 2022Hepatocellular Carcinoma
Bevacizumab use is questionable in liver cirrhosis with locally advanced HCCNovember 18, 2022Hepatocellular Carcinoma
Advanced HCC: Antidrug antibody levels tied to outcomes in patients on atezolizumab/bevacizumabNovember 18, 2022Hepatocellular Carcinoma
Commentary: Multifocal Hepatocellular Carcinoma, November 2022October 31, 2022Hepatocellular Carcinoma
Alpha-fetoprotein: A real-time monitor in HCC treatment with atezolizumab and bevacizumabOctober 24, 2022Hepatocellular Carcinoma
Unrecognized liver cirrhosis common, associated with worse prognosis in HCCOctober 24, 2022Hepatocellular Carcinoma
